Literature DB >> 22045557

Polyreactive antibodies in adaptive immune responses to viruses.

Hugo Mouquet1, Michel C Nussenzweig.   

Abstract

B cells express immunoglobulins on their surface where they serve as antigen receptors. When secreted as antibodies, the same molecules are key elements of the humoral immune response against pathogens such as viruses. Although most antibodies are restricted to binding a specific antigen, some are polyreactive and have the ability to bind to several different ligands, usually with low affinity. Highly polyreactive antibodies are removed from the repertoire during B-cell development by physiologic tolerance mechanisms including deletion and receptor editing. However, a low level of antibody polyreactivity is tolerated and can confer additional binding properties to pathogen-specific antibodies. For example, high-affinity human antibodies to HIV are frequently polyreactive. Here we review the evidence suggesting that in the case of some pathogens like HIV, polyreactivity may confer a selective advantage to pathogen-specific antibodies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22045557     DOI: 10.1007/s00018-011-0872-6

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  151 in total

1.  Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and btk.

Authors:  F Martin; J F Kearney
Journal:  Immunity       Date:  2000-01       Impact factor: 31.745

2.  Small rearrangements in structures of Fv and Fab fragments of antibody D1.3 on antigen binding.

Authors:  T N Bhat; G A Bentley; T O Fischmann; G Boulot; R J Poljak
Journal:  Nature       Date:  1990-10-04       Impact factor: 49.962

3.  Increased utilization of polyreactive B cells during periods of generalized immune activation.

Authors:  Y Ishigatsubo; A D Steinberg; A Krieg; D M Klinman
Journal:  Autoimmunity       Date:  1995       Impact factor: 2.815

Review 4.  CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire.

Authors:  P Casali; A L Notkins
Journal:  Immunol Today       Date:  1989-11

5.  Targeting human immunodeficiency virus type 1 with antibodies derived from patients with connective tissue disease.

Authors:  M Scherl; U Posch; G Obermoser; C Ammann; N Sepp; H Ulmer; M P Dierich; H Stoiber; B Falkensammer
Journal:  Lupus       Date:  2006       Impact factor: 2.911

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

9.  The specificity of cross-reactivity: promiscuous antibody binding involves specific hydrogen bonds rather than nonspecific hydrophobic stickiness.

Authors:  Leo C James; Dan S Tawfik
Journal:  Protein Sci       Date:  2003-10       Impact factor: 6.725

10.  Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity.

Authors:  Erin M Scherer; Michael B Zwick; Luc Teyton; Dennis R Burton
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

View more
  58 in total

1.  The griffithsin dimer is required for high-potency inhibition of HIV-1: evidence for manipulation of the structure of gp120 as part of the griffithsin dimer mechanism.

Authors:  Jie Xue; Bart Hoorelbeke; Ioannis Kagiampakis; Borries Demeler; Jan Balzarini; Patricia J Liwang
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

2.  Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.

Authors:  Feng Gao; Mattia Bonsignori; Hua-Xin Liao; Amit Kumar; Shi-Mao Xia; Xiaozhi Lu; Fangping Cai; Kwan-Ki Hwang; Hongshuo Song; Tongqing Zhou; Rebecca M Lynch; S Munir Alam; M Anthony Moody; Guido Ferrari; Mark Berrong; Garnett Kelsoe; George M Shaw; Beatrice H Hahn; David C Montefiori; Gift Kamanga; Myron S Cohen; Peter Hraber; Peter D Kwong; Bette T Korber; John R Mascola; Thomas B Kepler; Barton F Haynes
Journal:  Cell       Date:  2014-07-24       Impact factor: 41.582

3.  Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Rajesh Ringe; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines       Date:  2013-07

Review 4.  Serology in the 21st century: the molecular-level analysis of the serum antibody repertoire.

Authors:  Yariv Wine; Andrew P Horton; Gregory C Ippolito; George Georgiou
Journal:  Curr Opin Immunol       Date:  2015-07-10       Impact factor: 7.486

5.  A multispecific monoclonal antibody G2 recognizes at least three completely different epitope sequences with high affinity.

Authors:  Md Nuruddin Mahmud; Masayuki Oda; Daiki Usui; Yasuo Inoshima; Naotaka Ishiguro; Yuji O Kamatari
Journal:  Protein Sci       Date:  2017-09-04       Impact factor: 6.725

6.  Identification and characterization of a multispecific monoclonal antibody G2 against chicken prion protein.

Authors:  Yuji O Kamatari; Shinri Ohta; Yasuo Inoshima; Masayuki Oda; Takahiro Maruno; Yuji Kobayashi; Naotaka Ishiguro
Journal:  Protein Sci       Date:  2014-06-14       Impact factor: 6.725

7.  An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1.

Authors:  Mattia Bonsignori; Kevin Wiehe; Sebastian K Grimm; Rebecca Lynch; Guang Yang; Daniel M Kozink; Florence Perrin; Abby J Cooper; Kwan-Ki Hwang; Xi Chen; Mengfei Liu; Krisha McKee; Robert J Parks; Joshua Eudailey; Minyue Wang; Megan Clowse; Lisa G Criscione-Schreiber; M Anthony Moody; Margaret E Ackerman; Scott D Boyd; Feng Gao; Garnett Kelsoe; Laurent Verkoczy; Georgia D Tomaras; Hua-Xin Liao; Thomas B Kepler; David C Montefiori; John R Mascola; Barton F Haynes
Journal:  J Clin Invest       Date:  2014-03-10       Impact factor: 14.808

8.  The Regulation of Inherently Autoreactive VH4-34-Expressing B Cells in Individuals Living in a Malaria-Endemic Area of West Africa.

Authors:  Geoffrey T Hart; Munir Akkaya; Asiya S Chida; Chungwen Wei; Scott A Jenks; Christopher Tipton; Chenfeng He; Ben S Wendel; Jeff Skinner; Gunjan Arora; Kassoum Kayentao; Aissata Ongoiba; Ogobara Doumbo; Boubacar Traore; David L Narum; Ning Jiang; Peter D Crompton; Ignacio Sanz; Susan K Pierce
Journal:  J Immunol       Date:  2016-10-19       Impact factor: 5.422

Review 9.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

10.  A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism.

Authors:  Jordan D Dimitrov; Cyril Planchais; Tobias Scheel; Delphine Ohayon; Stephane Mesnage; Claudia Berek; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  J Biol Chem       Date:  2014-05-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.